OrbiMed’s Chemomab Therapeutics CMMB Stock Holding History

OrbiMed’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-235,248	Closed	-$1.09M	–	113
2025 Q2	$1.09M	Sell	235,248 -200,070	-46%	-$990K	0.03%	92
2025 Q1	$1.9M	Hold	435,318	–	–	0.05%	93
2024 Q4	$3.15M	Hold	435,318	–	–	0.06%	96
2024 Q3	$2.73M	Sell	435,318 -125,000	-22%	-$701K	0.05%	107
2024 Q2	$2.05M	Sell	560,318 -1	-0%	-$3	0.04%	104
2024 Q1	$1.75M	Hold	560,319	–	–	0.03%	105
2023 Q4	$1.14M	Hold	560,319	–	–	0.02%	103
2023 Q3	$2.01M	Hold	560,319	–	–	0.04%	112
2023 Q2	$2.95M	Hold	560,319	–	–	0.05%	110
2023 Q1	$3.56M	Sell	560,319 -84,225	-13%	-$661K	0.07%	109
2022 Q4	$8.25M	Hold	644,544	–	–	0.16%	78
2022 Q3	$6.42K	Hold	644,544	–	–	0.12%	99
2022 Q2	$9.54K	Hold	644,544	–	–	0.17%	91
2022 Q1	$12.4M	Hold	644,544	–	–	0.2%	92
2021 Q4	$17.8M	Hold	644,544	–	–	0.23%	89
2021 Q3	$28.6M	Hold	644,544	–	–	0.31%	80
2021 Q2	$49M	Hold	644,544	–	–	0.5%	57
2021 Q1	$74M	Buy	+644,544	New	+$128M	0.69%	43

Other funds holding CMMB

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

OrbiMed's CMMB Position: Q3 2025 in Review

OrbiMed sold out of Chemomab Therapeutics (CMMB) in Q3 2025, closing a stake of 235,248 shares — an estimated $1.09M sold.

OrbiMed first reported a position in CMMB in Q1 2021 and held it in 18 quarters. The position peaked at $74M in Q1 2021. 10 funds tracked by Wall St. Rank hold CMMB as of Q3 2025.

OrbiMed reported no remaining Chemomab Therapeutics position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 235,248 Chemomab Therapeutics shares in Q3 2025, an estimated $1.09M.
OrbiMed first reported a position in Chemomab Therapeutics in Q1 2021 and held it in 18 quarters.
OrbiMed's Chemomab Therapeutics position peaked at $74M in Q1 2021.
10 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.